# Phase 2a Trial to Evaluate Safety and Immunogenicity of COVID-19 Vaccine Strategies in HIV-infected/Uninfected Adults.

> **NCT05515042** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **The Aurum Institute NPC** · enrollment: 694 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Ad26.COV2.S (VAC31518, JNJ-78436735) Vaccine, SARS-CoV-2 rS (CovovaxTM), BNT162b2 (Pfizer)

## Key facts

- **NCT ID:** NCT05515042
- **Lead sponsor:** The Aurum Institute NPC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-25
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-12-31
- **Target enrollment:** 694 (ACTUAL)
- **Last updated:** 2024-07-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05515042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05515042, "Phase 2a Trial to Evaluate Safety and Immunogenicity of COVID-19 Vaccine Strategies in HIV-infected/Uninfected Adults.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05515042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*